Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT00692640
- Locations
- 🇺🇸
Investigational Site Number 1214, Nashville, Tennessee, United States
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- LungenClinic Grosshansdorf
- Target Recruit Count
- 260
- Registration Number
- NCT00678964
- Locations
- 🇩🇪
Fachkrankenhaus Coswig, Coswig, Germany
🇩🇪Schwerpunktpraxis Onkologie, Goslar, Germany
🇩🇪Fachklinik Diekholzen, Diekholzen, Germany
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 207
- Registration Number
- NCT00674973
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 583
- Registration Number
- NCT00673049
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT00663689
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
- Conditions
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00654420
A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT00642473
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00642746
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00640978
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Tarceva Italian Lung Optimization tRial
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- Fatebenefratelli and Ophthalmic Hospital
- Target Recruit Count
- 850
- Registration Number
- NCT00637910
- Locations
- 🇮🇹
D. Cotugno Hospital, Napoli, Italy
🇮🇹Ospedale di Circolo, Varese, Italy
🇮🇹Belcolle Hospital, Viterbo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.